Amycretin Research Peptide (RUO)

What is Amycretin?

Amycretin (INN zenagamtide; also referenced as NN9487) is a unimolecular GLP-1 and amylin receptor co-agonist: a single 68-amino-acid peptide in which a glucagon-like peptide-1 (GLP-1) receptor-agonist moiety and an amylin receptor-agonist moiety are covalently joined within one molecular entity. This hybrid design engages two complementary appetite- and metabolism-regulating pathways through one molecular entity.

Chemically, amycretin (CAS 3005889-81-3) has the molecular formula C343H550N94O116 and a molecular weight of approximately 7846.58 g/mol. It is investigational: it is in clinical development for obesity and type 2 diabetes and is not yet approved by the FDA, EMA or other major regulators for any indication.

How Amycretin Is Produced & Characterised

Amycretin is a long, structurally complex peptide: its 68-mer length, the dual-pharmacophore architecture and the internal linker all create opportunities for deletion sequences, diastereomers and incomplete couplings. Peptides of this class are typically produced by Fmoc solid-phase peptide synthesis (SPPS) with controlled coupling and conjugation chemistry, then purified on preparative dynamic axial compression (DAC) HPLC columns to resolve the target sequence from closely related impurities, and lyophilised to a stable powder.

Analytical characterisation of such peptides generally combines UPLC/HPLC for purity determination with LC-MS to confirm the intended sequence and to profile minor structural variants. These are the industry-standard approaches for preparing and assessing a peptide of this size and complexity.

Regulatory & Development Status

Amycretin is an investigational molecule. As of its current development stage it is in clinical trials for obesity and type 2 diabetes and has not been approved by the FDA, EMA or other major regulators for any indication. Investigational peptides of this kind are referenced in clinical-stage submissions through CTD Module 3 CMC sections (for IND/IMPD) and, where applicable, Drug Master File (DMF)-style dossiers, supported by analytical validation packages to ICH Q2(R1) and stability data.

Nothing here is medical or regulatory advice, and no therapeutic or efficacy claims are made for amycretin.

Research supply from Winhycare Pharma

Winhycare Pharma supplies research-grade Amycretin to research organisations and individual researchers for research and development purposes. Material is supplied at high purity (>99%) under stringent quality control with QC documentation, in secure packaging through global standard logistics, with dedicated technical assistance from our team. We focus on consistent quality and purity, reliable and timely supply, confidential and professional service, and long-term partnerships.

Research use only. Not for human or veterinary use, and not for use in food, drugs, medical devices or cosmetics.

To enquire, tell us the quantity you need, the purity grade, the documentation you require and the destination country. The buyer is responsible for complying with the import and use regulations that apply to Amycretin in their country.